TriVascular Technologies Inc (TRIV) Drops 6.19% on January 13

Equities Staff |

TriVascular Technologies Inc (TRIV) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 6.19% to $6.82, a loss of $-0.45 per share. Starting at an opening price of $7.25 a share, the stock traded between $6.59 and $7.32 over the course of the trading day. Volume was 44,752 shares over 289 trades, against an average daily volume of 24,755 shares and a total float of 20.57 million.

The losses send TriVascular Technologies Inc down to a market cap of $140.29 million. In the last year, TriVascular Technologies Inc has traded between $13.00 and $3.98, and its 50-day SMA is currently $7.01 and 200-day SMA is $6.42.

TriVascular Technologies Inc is a medical device company developing and marketing technologies to advance minimally invasive treatment of abdominal aortic aneurysms, or AAA.

TriVascular Technologies Inc is based out of Santa Rosa, CA and has some 307 employees. Its CEO is Christopher G. Chavez.

For a complete fundamental analysis analysis of TriVascular Technologies Inc, check out’s Stock Valuation Analysis report for TRIV. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.